Advertisement
BCTX vs IVVD
Which Stock Would AI Choose? BriaCell Therapeutics (BCTX) vs. Invivyd (IVVD) Stock Comparison
Key Takeaways
- BCTX and IVVD are both clinical-stage biotechs with binary, catalyst-driven risk profiles, but they operate in fundamentally different therapeutic areas.
- BCTX (BriaCell Therapeutics) is pre-revenue and focused on cancer immunotherapy, while IVVD (Invivyd) already generates product revenue from its COVID-19 antibody franchise.
- BCTX has shown stronger recent momentum, with a year-to-date gain of roughly 50%, while IVVD trades near the low end of its 52-week range amid Nasdaq listing concerns.
- IVVD carries a larger cash cushion (about $160 million) but faces a regulatory sunset on its core product, whereas BCTX is progressing a pivotal Phase 3 breast cancer trial.
- Both names remain highly speculative, and relative performance has been driven primarily by clinical and regulatory headlines rather than fundamentals.
- For further context, visit BCTX Major News and BCTX Today's Price Move, as well as IVVD Major News and IVVD Today's Price Move.
- Explore Trending AI Robots to see how automated strategies are positioning across these and other tickers.
Introduction
Investors comparing BCTX and IVVD are weighing two very different bets within the small-cap biotechnology space. BriaCell Therapeutics is an immuno-oncology developer advancing a personalized immunotherapy for advanced breast cancer, while Invivyd is an antibody-focused company targeting viral infectious diseases, led by its COVID-19 prevention franchise. Both stocks are unprofitable and driven by clinical data readouts and regulatory milestones, making them relevant to risk-tolerant traders and biotech-focused investors who prioritize catalysts and relative performance over current earnings. This stock comparison examines how the two names diverge in business model, market positioning, and recent momentum.
BCTX Overview and Recent Performance
BCTX, BriaCell Therapeutics Corp., is a clinical-stage immuno-oncology company developing targeted immunotherapies for cancer. Its lead candidate, Bria-IMT, is being evaluated in a pivotal Phase 3 trial (Bria-ABC) for metastatic breast cancer, and it holds U.S. Food and Drug Administration (FDA) Fast Track designation. The company also maintains earlier-stage programs, including personalized "off-the-shelf" immunotherapies and a prostate cancer candidate.
In recent weeks, BCTX has been supported by a steady flow of positive clinical and regulatory updates, including a seventh consecutive recommendation from an independent Data Safety Monitoring Board (DSMB) to continue its Phase 3 study and presentations of biomarker data at major oncology conferences. These developments have contributed to firmer sentiment and a notable year-to-date gain of roughly 50%. Despite this momentum, the stock remains highly volatile, with a beta above 1.5 and a 52-week range extending from about $2.60 to $13.90, reflecting the binary nature of its pipeline.
IVVD Overview and Recent Performance
IVVD, Invivyd, Inc., develops antibody therapies for the prevention and treatment of viral infectious diseases. Its commercial product, PEMGARDA (pemivibart), is authorized for pre-exposure prophylaxis of COVID-19 in certain adults, and the company is advancing VYD2311, a next-generation monoclonal antibody (a laboratory-made protein that mimics the immune system's ability to fight pathogens) through a Phase 3 program known as DECLARATION.
Recent market activity around IVVD has been mixed. The company reported roughly $14.3 million in quarterly product revenue, a year-over-year increase, and disclosed a strong cash position of about $160 million. However, the shares trade below $1.00 and near the lower end of their 52-week range, pressured by a Nasdaq bid-price deficiency notice, the prospect of dilution, and an FDA notice that could terminate PEMGARDA's Emergency Use Authorization (EUA) in 2027. Sell-side analysts have nonetheless maintained a broadly bullish consensus, citing the VYD2311 data readout as a key near-term catalyst.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of the platform's automated trading strategies. Tickeron offers hundreds of AI Trading Bots that collectively trade thousands of different tickers, but only the strongest and most suitable for current market conditions earn a place in this featured section. These bots vary widely in trading style, strategy, timeframe, performance, statistics, and the set of tickers they trade, allowing users to filter by criteria such as volatility, asset class, and risk tolerance. By surfacing only the best-performing, market-adapted strategies, the page helps traders evaluate systematic approaches rather than relying on emotion or guesswork. Explore Trending AI Robots to review available bots and consider how automated signals might complement your own research.
Head-to-Head Comparison
The most striking contrast between these two names is commercial maturity. IVVD already records product revenue from PEMGARDA, giving it a modest revenue base and a gross margin above 90%, even as it remains deeply unprofitable. BCTX, by contrast, is entirely pre-revenue, with its valuation resting almost exclusively on the outcome of its Phase 3 breast cancer trial.
Risk profiles also differ sharply. BCTX faces clinical execution and financing risk, with a relatively small cash balance and a history of dilutive offerings. IVVD holds substantially more cash but contends with a tangible regulatory overhang on its flagship product and a potential delisting if its share price does not recover. Sector exposure provides another distinction: BCTX sits in immuno-oncology, a crowded but high-reward field, while IVVD is concentrated in infectious-disease antibodies, a narrower market shaped by evolving COVID-19 demand and vaccine dynamics.
On momentum, BCTX has outperformed over the trailing year, while IVVD has been more rangebound near its lows. Yet analyst sentiment leans heavily on IVVD, where a Strong Buy consensus with price targets far above the current share price reflects expectations tied to VYD2311 data. The trade-off is clear: BCTX offers trend strength with concentrated clinical risk, whereas IVVD offers a larger cash buffer and a clearer regulatory pathway but faces headline-driven downside pressure.
Tickeron AI Verdict
Based on observable trend consistency, stability, and relative positioning, Tickeron's AI would likely lean toward BCTX at the current juncture. The stock has demonstrated stronger and more consistent upward momentum in recent weeks, supported by a sequence of constructive clinical milestones and a favorable relative performance profile. IVVD, while carrying a larger cash reserve and a more bullish analyst consensus, has shown weaker price stability and faces a more immediate overhang from its Nasdaq listing status and the regulatory uncertainty around PEMGARDA. Because both companies are highly speculative and catalyst-dependent, any assessment should be viewed as probabilistic and subject to rapid change as new clinical and regulatory data emerge.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BCTX is a Hold and IVVD is a Hold.
BCTX's RSI Oscillator recovers from oversold territory
The RSI Oscillator for BCTX moved out of oversold territory on November 04, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 44 similar instances when the indicator left oversold territory. In 39 of the 44 cases the stock moved higher. This puts the odds of a move higher at 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on November 06, 2026. You may want to consider a long position or call options on BCTX as a result. In 81 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 85%.
The Moving Average Convergence Divergence (MACD) for BCTX just turned positive on November 06, 2026. Looking at past instances where BCTX's MACD turned positive, the stock continued to rise in 34 of 41 cases over the following month. The odds of a continued upward trend are 83%.
Following a +23.82% 3-day Advance, the price is estimated to grow further. Considering data from situations where BCTX advanced for three days, in 204 of 259 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
BCTX moved below its 50-day moving average on November 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BCTX crossed bearishly below the 50-day moving average on October 19, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BCTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
BCTX broke above its upper Bollinger Band on November 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BCTX entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 18 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.428) is normal, around the industry mean (3.498). P/E Ratio (-4.702) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 56 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 62 (best 1 - 100 worst), indicating steady price growth. BCTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BCTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Momentum Indicator for IVVD turns negative, indicating new downward trend
IVVD saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 72 similar instances where the indicator turned negative. In 67 of the 72 cases, the stock moved further down in the following days. The odds of a decline are at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
IVVD moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for IVVD crossed bearishly below the 50-day moving average on October 09, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 12 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IVVD declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for IVVD entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where IVVD's RSI Oscillator exited the oversold zone, 39 of 45 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 87%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 49 of 58 cases where IVVD's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for IVVD just turned positive on November 02, 2026. Looking at past instances where IVVD's MACD turned positive, the stock continued to rise in 35 of 39 cases over the following month. The odds of a continued upward trend are 90%.
Following a +4.80% 3-day Advance, the price is estimated to grow further. Considering data from situations where IVVD advanced for three days, in 186 of 225 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 22 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 35 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.916) is normal, around the industry mean (3.498). P/E Ratio (-1.816) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (3.722) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 82 (best 1 - 100 worst), indicating slightly worse than average price growth. IVVD’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IVVD’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
BCTX | ||
|---|---|---|
OUTLOOK RATING 1..100 | 17 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 23 Undervalued | |
PROFIT vs RISK RATING 1..100 | 100 | |
SMR RATING 1..100 | 99 | |
PRICE GROWTH RATING 1..100 | 62 | |
P/E GROWTH RATING 1..100 | 56 | |
SEASONALITY SCORE 1..100 | 18 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
| BCTX | IVVD | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 89% | 2 days ago 87% |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 84% |
| Momentum ODDS (%) | 2 days ago 85% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 90% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 90% |
| TrendMonth ODDS (%) | 2 days ago 87% | 2 days ago 90% |
| Advances ODDS (%) | 6 days ago 79% | 22 days ago 83% |
| Declines ODDS (%) | 2 days ago 86% | 6 days ago 90% |
| BollingerBands ODDS (%) | 2 days ago 74% | N/A |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 90% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
BCTX’s FA Score shows that 1 FA rating(s) are green while IVVD’s FA Score has 1 green FA rating(s).
- BCTX’s FA Score: 1 green, 4 red.
- IVVD’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
BCTX’s TA Score shows that 4 TA indicator(s) are bullish while IVVD’s TA Score has 4 bullish TA indicator(s).
- BCTX’s TA Score: 4 bullish, 6 bearish.
- IVVD’s TA Score: 4 bullish, 5 bearish.
Price Growth
BCTX (@Biotechnology) experienced а +22.59% price change this week, while IVVD (@Biotechnology) price change was -1.22% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.
Reported Earning Dates
BCTX is expected to report earnings on Dec 10, 2026.
IVVD is expected to report earnings on Nov 12, 2026.
Industries' Descriptions
@Biotechnology (+4.90% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
BCTX and
Correlation & Price change
A.I.dvisor indicates that over the last year, BCTX has been loosely correlated with CANF. These tickers have moved in lockstep 59% of the time. This A.I.-generated data suggests there is some statistical probability that if BCTX jumps, then CANF could also see price increases.
| Ticker / NAME | Correlation To BCTX | 1D Price Change % | ||
|---|---|---|---|---|
| BCTX | 100% | -1.07% | ||
| CANF - BCTX | 59% Loosely correlated | -1.19% | ||
| ENVB - BCTX | 50% Loosely correlated | +4.86% | ||
| TECX - BCTX | 47% Loosely correlated | +0.37% | ||
| ALLR - BCTX | 44% Loosely correlated | -3.49% | ||
| TAOX - BCTX | 35% Loosely correlated | -5.15% | ||
More | ||||
IVVD and
Correlation & Price change
A.I.dvisor indicates that over the last year, IVVD has been loosely correlated with BCTX. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if IVVD jumps, then BCTX could also see price increases.
| Ticker / NAME | Correlation To IVVD | 1D Price Change % | ||
|---|---|---|---|---|
| IVVD | 100% | -3.66% | ||
| BCTX - IVVD | 43% Loosely correlated | -1.07% | ||
| IMMX - IVVD | 36% Loosely correlated | -2.57% | ||
| CANF - IVVD | 35% Loosely correlated | -1.19% | ||
| HCWB - IVVD | 35% Loosely correlated | -0.42% | ||
| AXON - IVVD | 34% Loosely correlated | -0.21% | ||
More | ||||